专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010109226A2 SCAFFOLD 审中-公开
标题翻译：脚手架
公开(公告)号：WO2010109226A2
公开(公告)日：2010-09-30
申请号：PCT/GB2010050485
申请日：2010-03-23
申请人： UNIV LEEDS , UNIV BRADFORD , NEOTHERIX LTD , WOOD SIMON , YANG XUEBIN , DE MATAS MARCEL , IDDON PETER , RAXWORTHY MICHAEL
发明人： WOOD SIMON , YANG XUEBIN , DE MATAS MARCEL , IDDON PETER , RAXWORTHY MICHAEL
IPC分类号： A61L27/18 , A61L27/54 , A61L27/56
CPC分类号： A61L27/3804 , A61L27/18 , A61L27/50 , A61L27/54 , A61L2300/224 , A61L2300/404 , A61L2300/442 , A61L2300/62 , C08L67/04
摘要： The present invention provides a polymeric scaffold containing an antibacterial photoactive drug and optionally comprising seeded cells such as stem cells. The invention also includes methods of using the scaffold for tissue regeneration, prevention or reduction of infection whilst tissue regeneration occurs, methods for improving graft or implant survival, promoting scaffold integration and tissue repair and wound healing.
摘要翻译：本发明提供含有抗菌光活性药物和任选地包含接种细胞如干细胞的聚合物支架。本发明还包括在组织再生发生时使用支架用于组织再生，预防或减少感染，改善移植物或植入物存活的方法，促进支架整合和组织修复和伤口愈合的方法。

2. 发明申请

WO2005011647A3 PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：药物组合物
公开(公告)号：WO2005011647A3
公开(公告)日：2005-07-28
申请号：PCT/GB2004003241
申请日：2004-07-27
申请人： ASTRAZENECA AB , ASTRAZENECA UK LTD , BATEMAN NICOLA FRANCES , GELLERT PAUL RICHARD , DE MATAS MARCEL , POTTS ALISON MARGARET
发明人： BATEMAN NICOLA FRANCES , GELLERT PAUL RICHARD , DE MATAS MARCEL , POTTS ALISON MARGARET
IPC分类号： A61K9/14 , A61K9/16 , A61K9/20 , A61K9/28 , A61K31/5377 , A61K47/12 , A61K47/38
CPC分类号： A61K31/5377 , A61K9/145 , A61K9/146 , A61K9/1617 , A61K9/1652 , A61K9/2018 , A61K9/2054 , A61K9/2866 , A61K47/12 , A61K47/38
摘要： An immediate release pharmaceutical composition comprising 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically-acceptable salt thereof (the Agent); a water-soluble acid; and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether. The claimed compositions inhibit the rate of precipitation of the Agent from solution and/or provide enhanced solubilisation of the agent at pH levels similar to those of the upper GI tract. The claimed compositions are expected to be useful in reducing inter-patient and/or intra-patient variability in exposure to the Agent.
摘要翻译：包含4-（3'-氯-4'-氟苯胺基）-7-甲氧基-6-（3-吗啉代丙氧基）喹唑啉或其药学上可接受的盐（试剂）的速释药物组合物; 水溶性酸; 和水溶性纤维素醚或水溶性纤维素醚的酯。要求保护的组合物抑制药剂从溶液中沉淀的速率和/或在与上部胃肠道相似的pH水平下提供药剂增强的溶解。预期要求保护的组合物可用于减少暴露于药剂的患者间和/或患者内的可变性。

3. 发明申请

WO2012107765A2 PARTICLE FORMULATION 审中-公开
标题翻译：颗粒配方
公开(公告)号：WO2012107765A2
公开(公告)日：2012-08-16
申请号：PCT/GB2012050283
申请日：2012-02-09
申请人： KUECEPT LTD , LENA NANOCEUTICS LTD , SAUNDERS MARK HENRY , DE MATAS MARCEL , JONES JASON ROBERT
发明人： SAUNDERS MARK HENRY , DE MATAS MARCEL , JONES JASON ROBERT
IPC分类号： A61K9/00
CPC分类号： A61K9/1617 , A61K9/0075 , A61K9/008 , A61K9/1635 , A61K9/1652 , A61K31/137 , A61K31/192 , A61K31/56 , A61K31/64 , A61K45/06 , A61K2300/00
摘要： The present inventions relates to combination particle formulations suitable for use in an inhaler formulation comprising a plurality of pharmacologically active ingredients characterized in that the pharmacologically active ingredients are crystalline. The present invention further comprises a particle formulation suitable for use in an inhalation formulation comprising a plurality of pharmacologically active ingredients, for example crystalline pharmacologically active ingredients characterized in that the ratio of the pharmacologically active substances has a distribution of less than ±5% of the target ratio as measured by Impactor testing. Particularly particle formulations prepared from nanoparticles, for example by spray drying of an aqueous suspension of nanoparticles. The invention further comprises methods for making said particle formulations and method of using said particle formulations in therapeutic treatments to achieve co-localisation of agents in the body, particularly when delivered as inhaled formulations to the human airways and lungs.
摘要翻译：本发明涉及适用于包含多种药理活性成分的吸入制剂的组合颗粒制剂，其特征在于药理活性成分是结晶的。本发明进一步包括适用于包含多种药理学活性成分，例如结晶药理学活性成分的吸入制剂中的颗粒制剂，其特征在于药理学活性物质的比例具有小于药物活性成分的±5％目标比率由冲击试验测量。特别是由纳米颗粒制备的颗粒制剂，例如通过喷雾干燥纳米颗粒的含水悬浮液。本发明进一步包括制备所述颗粒制剂的方法和在治疗处理中使用所述颗粒制剂的方法，以实现试剂在体内的共定位，特别是当作为吸入制剂递送至人气道和肺时。

4. 发明申请

WO03035043A3 PHARMACEUTICAL FORMULATION COMPRISING MORE THAN 15% TAMOXIFEN 审中-公开
标题翻译：包含超过15％的他莫昔芬的药物制剂
公开(公告)号：WO03035043A3
公开(公告)日：2003-06-05
申请号：PCT/GB0204835
申请日：2002-10-23
申请人： ASTRAZENECA AB , ASTRAZENECA UK LTD , DE MATAS MARCEL
发明人： DE MATAS MARCEL
IPC分类号： C07D249/08 , A61K9/16 , A61K9/20 , A61K9/28 , A61K9/30 , A61K9/36 , A61K31/138 , A61K31/4196 , A61K47/02 , A61K47/12 , A61K47/24 , A61K47/26 , A61K47/32 , A61K47/38 , A61P5/32 , A61P35/00 , A61P43/00 , A61K31/135 , A61K31/41
CPC分类号： A61K9/2866 , A61K9/2054
摘要： The invention provides a pharmaceutical formulation comprising >15 % tamoxifen (w/w). In a further embodiments of the invention the invention provides said formulation further comprising from about 0.45 % to 1 % (w/w) anastrozole. The invention also provides said formulation in the form of a tablet and processes for the preparation of said formulation.
摘要翻译：本发明提供包含> 15％他莫昔芬（w / w）的药物制剂。在本发明的另一个实施方案中，本发明提供所述制剂还包含约0.45％至1％（w / w）的阿那曲唑。本发明还提供片剂形式的所述制剂和用于制备所述制剂的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式